Prognostic value of cytogenetics in the population of 405 patients with available karyotype
Cytogenetic subgroup* . | Favorable . | Intermediate . | Unfavorable . | Unknown significance . | P . |
|---|---|---|---|---|---|
| Patients, no. | 56 | 215 | 80 | 54 | — |
| CR, no. (%) | 53 (95) | 173 (80) | 45 (56) | 41 (76) | < .0001 |
| Cumulative incidence of relapse† | .20 | ||||
| 2-year estimate, % (95% Cl) | 49.0 (35.4-62.7) | 44.5 (37.1-51.9) | 60 (45.2-74.8) | 56.1 (40.5-71.7) | — |
| 5-year estimate, % (95% Cl) | 49.0 (35.4-62.7) | 55.5 (48.1-63.0) | 64.4 (49.8-79.1) | 63.4 (48.2-78.7) | — |
Cytogenetic subgroup* . | Favorable . | Intermediate . | Unfavorable . | Unknown significance . | P . |
|---|---|---|---|---|---|
| Patients, no. | 56 | 215 | 80 | 54 | — |
| CR, no. (%) | 53 (95) | 173 (80) | 45 (56) | 41 (76) | < .0001 |
| Cumulative incidence of relapse† | .20 | ||||
| 2-year estimate, % (95% Cl) | 49.0 (35.4-62.7) | 44.5 (37.1-51.9) | 60 (45.2-74.8) | 56.1 (40.5-71.7) | — |
| 5-year estimate, % (95% Cl) | 49.0 (35.4-62.7) | 55.5 (48.1-63.0) | 64.4 (49.8-79.1) | 63.4 (48.2-78.7) | — |
According to the SWOG/ECOG classification.23
Using the Gray test with allogeneic BMT in first CR and death in first CR considered as competing events. The P value was .28 when the favorable subgroup was compared to the nonfavorable subgroups and .09 when the unfavorable group was compared to the nonunfavorable subgroups.